Loading...
XNYS
EW
Market cap52bUSD
Jul 09, Last price  
91.33USD
1D
-2.47%
1Q
17.29%
Jan 2017
192.41%
IPO
6,724.18%
Name

Edwards Lifesciences Corp

Chart & Performance

D1W1MN
XNYS:EW chart
P/E
48.99
P/S
8.67
EPS
1.86
Div Yield, %
Shrs. gr., 5y
-1.50%
Rev. gr., 5y
6.70%
Revenues
6.07b
+11.55%
1,037,000,0001,091,100,0001,237,700,0001,321,400,0001,447,000,0001,678,600,0001,899,600,0002,045,500,0002,322,900,0002,493,700,0002,963,700,0003,435,300,0003,722,800,0004,348,000,0004,386,300,0005,232,500,0005,382,400,0005,010,000,0005,439,500,0006,067,600,000
Net income
1.07b
-74.28%
130,500,000113,000,000128,900,000229,100,000218,000,000236,700,000293,200,000391,700,000811,100,000494,900,000569,500,000622,100,000722,200,0001,046,900,000823,400,0001,503,100,0001,521,900,0001,402,400,0004,174,600,0001,073,500,000
CFO
1.60b
+194.15%
230,800,000210,200,000153,200,000165,300,000251,400,000314,500,000373,800,000472,700,0001,022,300,000549,700,000704,400,0001,000,700,000926,800,0001,179,400,0001,054,300,0001,732,100,0001,218,200,000895,800,000542,300,0001,595,200,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Edwards Lifesciences, a global medical technology leader, specializes in developing advanced solutions for structural heart conditions and critical care/surgical monitoring. Operating across the U.S., Europe, Japan, and other international markets, the company provides transcatheter heart valve therapies for minimally invasive replacement and repair, specifically targeting mitral and tricuspid valve diseases. Its innovative offerings include the PASCAL and Cardioband transcatheter valve repair systems. Beyond transcatheter devices, Edwards Lifesciences manufactures a comprehensive range of surgical structural heart products, such as the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex replacements, and the HARPOON Beating Heart Mitral Valve Repair System for degenerative mitral regurgitation. The firm also delivers crucial critical care solutions, including sophisticated hemodynamic monitoring systems for assessing cardiac function and fluid balance in surgical and ICU settings, alongside the Acumen Hypotension Prediction Index software, which proactively warns clinicians about impending dangerously low blood pressure. Products are distributed via an in-house sales team and independent distributors. Established in 1958, Edwards Lifesciences Corporation is headquartered in Irvine, California.
IPO date
Mar 27, 2000
Employees
17,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT